JSAM
J. Safra Asset Management Portfolio holdings
AUM
$1.38B
1-Year Return
16.76%
This Quarter Return
+5.53%
1 Year Return
+16.76%
3 Year Return
+74.03%
5 Year Return
+124.37%
10 Year Return
–
AUM
$1.05B
AUM Growth
+$61.3M
(+6.2%)
Cap. Flow
+$17.7M
Cap. Flow
% of AUM
1.68%
Top 10 Holdings %
Top 10 Hldgs %
75.78%
Holding
322
New
54
Increased
182
Reduced
11
Closed
24
Top Buys
| 1 |
Invesco S&P 500 Equal Weight ETF
RSP
|
$38.4M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$33.9M |
| 3 |
SPDR Gold Trust
GLD
|
$6.97M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$4.78M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$4.14M |
Top Sells
| 1 |
VanEck Semiconductor ETF
SMH
|
$30.5M |
| 2 |
Invesco QQQ Trust
QQQ
|
$24.7M |
| 3 |
iShares Core S&P Small-Cap ETF
IJR
|
$23.5M |
| 4 |
iShares Russell 1000 Growth ETF
IWF
|
$6.6M |
| 5 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$2.65M |
Sector Composition
| 1 | Technology | 1.16% |
| 2 | Consumer Discretionary | 0.55% |
| 3 | Financials | 0.43% |
| 4 | Communication Services | 0.39% |
| 5 | Healthcare | 0.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
10x Genomics
TXG
$1.75B
| $884 | ﹤0.01% |
+39
| New | +$884 |
|
277
Veeva Systems
VEEV
$44.6B
| $843 | ﹤0.01% |
+4
| New | +$843 |
|
278
Bruker
BRKR
$4.67B
| $777 | ﹤0.01% |
+11
| New | +$777 |
|
279
Royalty Pharma
RPRX
$15.8B
| $733 | ﹤0.01% |
+26
| New | +$733 |
|
280
Procept Biorobotics
PRCT
$2.24B
| $716 | ﹤0.01% |
+9
| New | +$716 |
|
281
Privia Health
PRVA
$2.87B
| $705 | ﹤0.01% |
+39
| New | +$705 |
|
282
Nuvalent
NUVL
$5.92B
| $694 | ﹤0.01% |
+7
| New | +$694 |
|
283
Molina Healthcare
MOH
$9.45B
| $684 | ﹤0.01% |
+2
| New | +$684 |
|
284
Alignment Healthcare
ALHC
$3.16B
| $585 | ﹤0.01% |
+51
| New | +$585 |
|
285
Lifestance Health
LFST
$2.09B
| $541 | ﹤0.01% |
+78
| New | +$541 |
|
286
Merus
MRUS
$5.09B
| $430 | ﹤0.01% |
+9
| New | +$430 |
|
287
Xenon Pharmaceuticals
XENE
$3.03B
| $425 | ﹤0.01% |
+11
| New | +$425 |
|
288
Arcellx
ACLX
$4B
| $414 | ﹤0.01% |
+5
| New | +$414 |
|
289
MoonLake Immunotherapeutics
MLTX
$3.83B
| $395 | ﹤0.01% |
+8
| New | +$395 |
|
290
Dyne Therapeutics
DYN
$2.01B
| $372 | ﹤0.01% |
+11
| New | +$372 |
|
291
Phreesia
PHR
$1.67B
| $364 | ﹤0.01% |
+16
| New | +$364 |
|
292
Agilon Health
AGL
$514M
| $363 | ﹤0.01% |
97
-4,107
| -98% | -$15.4K |
|
293
BioNTech
BNTX
$26.9B
| $355 | ﹤0.01% |
+3
| New | +$355 |
|
294
Keros Therapeutics
KROS
$640M
| $339 | ﹤0.01% |
+6
| New | +$339 |
|
295
Viridian Therapeutics
VRDN
$1.51B
| $327 | ﹤0.01% |
+14
| New | +$327 |
|
296
Janux Therapeutics
JANX
$1.44B
| $324 | ﹤0.01% |
+7
| New | +$324 |
|
|
CRGX
297
DELISTED
CARGO Therapeutics
CRGX
| $244 | ﹤0.01% |
+14
| New | +$244 |
|
298
Immunocore
IMCR
$1.85B
| $157 | ﹤0.01% |
+5
| New | +$157 |
|
299
Adient
ADNT
$1.99B
| – | – |
-43
| Closed | -$1.06K |
|
300
Crown Holdings
CCK
$10.9B
| – | – |
-11
| Closed | -$818 |
|